Shukra Pharma wins rights to distribute Wockhardt advanced anti-infective formulations across India
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2025-09-11 06:45 GMT | Update On 2025-09-11 06:45 GMT
Advertisement
New Delhi: Wockhardt, a global pharma company, has authorised Shukra Pharma to represent, distribute, and manage its products across all ESIC/ESIS Hospitals, Defence Hospitals / AFMSD / DGAFMS units across India.
On Wednesday, Shukra Pharmaceuticals said that it entered into a strategic non-exclusive Pan-India distribution arrangement with Wockhardt Ltd.
According to an exchange filing, the authorization is effective from September 9, 2025 and is valid until March 2026.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.